3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Nivolumab
3
Quality of Life
2
Magnetic Resonance Spectroscopy
2
Gemcitabine
2
Fluorodeoxyglucose F18
2
Drug Therapy
2
Cisplatin
2
trametinib
1
tislelizumab
1
spartalizumab
1
seribantumab
1
pembrolizumab
1
pazopanib
1
milademetan
1
ivosidenib
1
entrectinib
1
enasidenib
1
durvalumab
1
crenigacestat
1
apixaban
1
alectinib
1
abemaciclib
1
Surveys and Questionnaires
1
Specimen Handling
1
Rivaroxaban
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Metformin
1
LY3023414
1
LY2940680
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
apixaban
×
Sarcoma
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled